Examine the Impact of Early Education on COPD Management

July 23, 2021 updated by: University of Alberta

Examine the Impact of Early Chronic Disease Management Education Following Hospital Discharge in Acute Exacerbation of COPD

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease primarily caused by smoking. COPD creates a tremendous burden to the healthcare system, as disease exacerbations result in frequent, prolonged hospitalizations. While originally considered a disease specific to the lung, data has shown that COPD is associated with substantial cardiovascular (CV) morbidity and mortality. Exacerbations of COPD requiring hospitalization result in marked patient deterioration, and heightened CV risk. The cause of the increased CV risk with stable COPD, and the exaggerated CV risk during exacerbations of the disease are unknown; however, it may be due to chronic inflammation which is exacerbated with a flare-up of the disease, and/or chronic inactivity which is similarly worsened with bed-rest during a hospitalization. Despite the impact of COPD on healthcare, there are relatively few studies examining how COPD inpatient care impacts on patient outcomes, inflammation and CV risk. Disease management programs, such as pulmonary rehabilitation and patient self-management education, are part of guideline therapy for COPD; however, these are not regularly implemented following a hospitalization, and how these interventions affect patient outcomes, behavior, physical activity, inflammation and CV risk have not been well studied. The proposed long-term project will examine how early referral to chronic disease management programs after hospital discharge, affect patient outcomes. This study will provide invaluable information about outpatient management for a disease which has a tremendous impact on healthcare.

Study Overview

Detailed Description

Purpose: To examine the impact of early pulmonary education (PE) following hospital discharge on QoL, pulmonary/CV outcomes and AECOPD hospitalizations.

Rationale: Studies have shown that education improves self-efficacy and QoL in COPD. Whether these improvements translate to increased exercise tolerance, physical activity, reduced CV risk and hospitalizations in patients recently discharged from hospital requires examination.

Hypothesis: Patients who receive early education will have improved QoL, pulmonary/CV outcomes, and less COPD hospitalizations in the 6 months following hospital discharge. Education will improve self efficacy, physical activity and QoL while reducing CV risk as compared to usual care.

Study Design & Subject Recruitment: In Calgary, patients discharged following an AECOPD hospitalization are referred to the Calgary COPD and Asthma Program (CCAP) where they are seen by a Certified Respiratory Educator 1-2 times within the month following discharge. For this study, patients will be recruited from the CCAP program and randomized into receiving usual care; general education sessions over the month following discharge, or the experimental arm; focused education following discharge from hospital. Patients found to have an acute cardiac injury, mobility issues or residence outside the greater Calgary area will be excluded. All education visits will be 1hr in length, and occur at a local outpatient clinic. The education will focus on patient self-management and will use Living Well with COPD supporting literature (www.livingwellwithcopd.com) designed to improve patient self-management and physical activity. All patients will be followed up 6 months after discharge and will be interviewed to assess disease status, management review and if there has been a history of recurrence or relapse of the AECOPD. Hospital admissions and length of stay will be obtained through electronic medical records as described above. Patient assessments will include: quality of life, 6min walk, dyspnea, self-efficacy, physical activity, pulse wave velocity (PWV), vascular function and systemic inflammation (TNF, MMP-2, IL-6 and CRP). All data will be collected before, immediately and 6 months after education. The control group will have the same data collected at the same scheduled time. See above for descriptions of methods.

Data Handling: Data will be entered onto a secure anonymized database.

Data Analysis: The influence of education on QoL, 6min walk, dyspnea, self-efficacy, physical activity, pulse wave velocity, vascular function and systemic inflammation will be evaluated using a multivariate mixed-model multivariate analysis of variance (MANOVA) with treatment (education vs. usual care) being a fixed between-group variable and time (pre, immediate post, 6months post) as a repeated variable.

Sample size: Based on previous work, a total sample size of 140 (70 in each group) will be sufficient to detect a clinically significant difference in QoL and a significant difference in hospital readmission rates. Based on outhe investigators r recent work, this sample could detect a 10% difference in PWV and physical activity.

Study Type

Interventional

Enrollment (Anticipated)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alberta
      • Calgary, Alberta, Canada, T2N4Z6
        • University of Calgary

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • All patients admitted to the pulmonary ward for an AECOPD will be offered participation into this arm of the study.

Exclusion Criteria:

  • Patients found to have an acute cardiac injury during admission, mobility issues or residence outside the greater Calgary area will be excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Early Pulmonary Education (EPE)
Patients randomized to EPE will receive focused education sessions by a Certified Respiratory Educator. Education sessions will start within two weeks of discharge from hospital.
Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
Other: Usual Care
Patients randomized to usual care will receive general education sessions by a Certified Respiratory Educator within the month of being discharged.
Patients enrolled in usual care will receive general education sessions following discharge from hospital.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vascular Function
Time Frame: Change in baseline vascular function post respiratory education and 6 months
Peripheral arterial tone (PAT) and arterial stiffness will be used to assess vascular function.
Change in baseline vascular function post respiratory education and 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inflammatory markers (IL-6)
Time Frame: Change in baseline IL-6 post respiratory education and 6 months
IL-6: is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine
Change in baseline IL-6 post respiratory education and 6 months
Inflammatory markers (TNF-alpha)
Time Frame: Change in baseline TNF-alpha post respiratory education and 6 months
TNF-alpha
Change in baseline TNF-alpha post respiratory education and 6 months
Inflammatory markers (MMP-2)
Time Frame: Change in baseline MMP-2 post respiratory education and 6 months
MMP-2
Change in baseline MMP-2 post respiratory education and 6 months
Inflammatory markers (CRP)
Time Frame: Change in baseline CRP post respiratory education and 6 months
CRP - -reactive protein is a non-specific serum marker of inflammation (range <8 is normal)
Change in baseline CRP post respiratory education and 6 months
Quality of Life (QoL)
Time Frame: Change in baseline Quality of Life post respiratory education and 6 months
COPD Assessment Tool (CAT) will be used to assess quality of life.
Change in baseline Quality of Life post respiratory education and 6 months
Quality of Life (QoL)
Time Frame: Change in baseline Quality of Life post respiratory education and 6 months
St. George Respiratory Questionnaire (SGRQ) will be used to assess quality of life.
Change in baseline Quality of Life post respiratory education and 6 months
Quality of Life (QoL)
Time Frame: Change in baseline Quality of Life post respiratory education and 6 months
COPD Self Efficacy Scale will be used to assess quality of life.
Change in baseline Quality of Life post respiratory education and 6 months
Dyspnea
Time Frame: Change in baseline dyspnea post respiratory education and 6 months
Modified Medical Research Council Dyspnea Scale (MMRC) will be used to assess dyspnea (breathlessness)
Change in baseline dyspnea post respiratory education and 6 months
Physical Activity
Time Frame: Change in baseline physical activity post respiratory education and 6 months
Physical activity will be assessed by an accelerometer worn on the patients wrist or upper arm
Change in baseline physical activity post respiratory education and 6 months
Hospital Re-admissions
Time Frame: One year re-admission
Re-admission rates for AECOPD will be documented
One year re-admission

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2015

Primary Completion (Actual)

December 1, 2019

Study Completion (Actual)

December 1, 2020

Study Registration Dates

First Submitted

March 20, 2015

First Submitted That Met QC Criteria

March 24, 2015

First Posted (Estimate)

March 25, 2015

Study Record Updates

Last Update Posted (Actual)

July 27, 2021

Last Update Submitted That Met QC Criteria

July 23, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • REB14-0504
  • AIHS-CRIO Project Grant (Other Identifier: Alberta Innovated Health Solutions (AIHS))

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trials on Pulmonary Education (PE)

3
Subscribe